AngioDynamics Inc. has filed an 8-K with the Securities and Exchange Commission (SEC) announcing significant leadership changes within the company. The filing, dated October 8, 2026, reveals that Eric Honroth will take over as President and Chief Executive Officer (CEO) effective November 2, 2026. This transition comes as James Clemmer, the current CEO, prepares to retire.
The appointment of a new CEO is crucial for investors and stakeholders as it can influence the company’s strategic direction and operational performance. Understanding the leadership behind a company can provide insights into its future growth and stability.
Background on AngioDynamics
AngioDynamics Inc. is a medical technology company that specializes in surgical and medical instruments and apparatus. Founded in 1985 and based in Latham, New York, the company focuses on developing innovative solutions for minimally invasive procedures in various medical fields.
The Form 8-K is a current report that companies must file with the SEC to announce major events that shareholders should know about. This includes changes in executive leadership, material agreements, and other significant corporate events.
Details from the Filing
According to the filing (accession number 0001140361-26-039019), on October 3, 2026, AngioDynamics entered into an employment agreement with Eric Honroth, who will serve as the new CEO. The agreement outlines that Honroth will receive a base salary of $735,000 per year, with eligibility for annual bonuses targeted at 95% of his base salary.
The filing further states, "Mr. Honroth will receive a long-term incentive award with a grant-date value equal to $1,487,116," which includes a combination of restricted stock units and performance share units. Additionally, he will receive a one-time award of restricted stock units valued at $450,000 and a cash sign-on bonus of $350,000.
James Clemmer, who has been with AngioDynamics since April 2016, will retire on or before November 30, 2026. His retirement is not attributed to any disagreements with the company.
Impact of the Filing
The changes in leadership at AngioDynamics may affect various stakeholders, including employees, investors, and customers. For employees, a new CEO can bring changes to the company culture and operational strategies. Investors will be keenly watching how Honroth's leadership style and experience will influence the company's performance moving forward.
Honroth's background includes significant experience in the medical technology sector, having previously served as President Life Science at Getinge AB and held leadership roles at other notable companies such as Abbott Vascular and Boston Scientific. This experience may instill confidence in investors regarding the company's future direction.
What’s Next
The filing does not specify what happens next beyond the appointment of Eric Honroth as CEO. However, stakeholders will likely be looking for updates on the company’s strategic initiatives and performance metrics following this leadership transition.